Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but additional data are needed about the effect of the drug on inpatient and outpatient events that reflect worsening...

Descripción completa

Detalles Bibliográficos
Autores principales: Packer, Milton, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Brueckmann, Martina, Jamal, Waheed, Zeller, Cordula, Schnaidt, Sven, Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834905/
https://www.ncbi.nlm.nih.gov/pubmed/33081531
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834905/
https://www.ncbi.nlm.nih.gov/pubmed/33081531
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051783

Ejemplares similares